1. Shewach D, Plunkett W (1982) Correlation of cytotoxicity with total intracellular exposure to 9-ß-D-arabinofuranosyladenine 5’-triphos- phate. Cancer Res 46: 1581 - 1585
2. Kufe D, Spriggs D, Egan EM, Monroe D (1984) Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64: 54 - 60
3. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharma-cologically directed ara-C therapy for refractory leukemia. Semin Oncol 12 [Suppl 3]: 20 - 30
4. Liliemark JO, Plunkett W, Dixon DO (1985) Relationship of L-ß-D-arabinofuranosylcytosine in plasma to L-ß-D-arabinofuranosylcytosine ß-triphosphate levels in leukemic cells during treatment with high-dose 1-ß-D-arabinofuranosylcytosine. Cancer Res 45: 5952 - 5957
5. Kantarjian H, Estey E, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81: 387 - 394